Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

By A. Goodman, S. Kato, L. Bazhenova, S. Patel, G. Frampton, Vincent A. Miller, P. Stephens, G. Daniels, Razelle Kurzrock. Molecular Cancer Therapeutics, 2017

1,964 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/e93b6f5089daa89343fc2bf3afde429d44093bc9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Nicholas McGranahan
2. Charles Swanton

In Oncology

1. Nicholas McGranahan
2. M. Hellmann
3. Razelle Kurzrock
4. J. Wolchok
5. M. Callahan
6. Charles Swanton

In Pulmonary and Respiratory Medicine

1. Charles Swanton
2. Nicholas McGranahan

Citations in the corpus

• Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “, 2017), and in a report of 17 patients with melanoma treated with combination immunotherapy, TMB did not correlate with response (Goodman et al., 2017).”
• Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors (2018, background): “McGranahan N et al. found that homogeneous tumor with high TMB associated with increased clinical benefits and sensitivity to anti-PD-1/PD-L1 therapy [65].”
• Liquid biopsy: current technology and clinical applications (2022, background): “Tumor mutational burden (TMB) detected by next-generation sequencing of tumor tissue has been shown to correlate with response to immune checkpoint inhibitors [36].”